Medical Disposables & Supplies Ltd has appointed veteran pharmaceutical executive Duke Holness to its board as the company works to arrest two consecutive years of net losses.
Chief Executive Kurt Boothe said Holness’ experience in profit-and-loss management and regional operations would strengthen board oversight. “MDS is confident that his impact at the board level will translate into the future growth and development of the company,” Boothe said, while declining to comment on speculation of further board changes.
MDS said Holness joined the board on February 4, bringing more than three decades of senior leadership experience in pharmaceuticals and consumer goods across the Caribbean and Latin America. His appointment comes as the company navigates flat revenue and persistent bottom-line pressure.
For the nine months ended December 2025, MDS reported revenue of $2.93 billion, a 2.0 per cent increase over the $2.87 billion posted in the same period a year earlier. The October-to-December quarter was softer, however, with revenue falling 6.0 per cent to $924.7 million from $987.28 million in the comparable 2024 quarter. The net loss over nine months totalled $78.6 million from $103.5 million a year earlier.
MDS previously reported a consolidated net profit of $80.2 million in financial year 2023 and $10.5 million in 2022.
Holness previously held senior roles at GlaxoSmithKline Pharmaceuticals, as vice-president and general manager overseeing operations in 27 markets, and later led Exeltis Pharmaceuticals in Central America and the Caribbean.
neville.graham@gleanerjm.com
